Figure 1.
HLA-B, -DRB1, -DPB1, and -C mismatching and clinical outcome. Adjusted probabilities are derived from multivariable models. (A) HLA-B leader and overall survival. (B) HLA-DRB1 and relapse. (C) HLA-DPB1 and overall survival. (D) HLA-C and chronic GVHD. Survival models (A, C) were adjusted for comorbidities, disease type and status, recipient and donor age, recipient-donor cytomegalovirus match, time from diagnosis to transplant and stratified by graft type. Model A was also adjusted for HLA-DPB1. Model C was also adjusted for HLA-B leader. Relapse model (B) adjusted for conditioning intensity and time from diagnosis to transplant and stratified for disease type and status. Chronic GVHD model (D) was adjusted for disease type, recipient age, recipient-donor sex match, time from diagnosis to transplant, and graft type.

HLA-B, -DRB1, -DPB1, and -C mismatching and clinical outcome. Adjusted probabilities are derived from multivariable models. (A) HLA-B leader and overall survival. (B) HLA-DRB1 and relapse. (C) HLA-DPB1 and overall survival. (D) HLA-C and chronic GVHD. Survival models (A, C) were adjusted for comorbidities, disease type and status, recipient and donor age, recipient-donor cytomegalovirus match, time from diagnosis to transplant and stratified by graft type. Model A was also adjusted for HLA-DPB1. Model C was also adjusted for HLA-B leader. Relapse model (B) adjusted for conditioning intensity and time from diagnosis to transplant and stratified for disease type and status. Chronic GVHD model (D) was adjusted for disease type, recipient age, recipient-donor sex match, time from diagnosis to transplant, and graft type.

Close Modal

or Create an Account

Close Modal
Close Modal